Saturday 17 October 2026
Export NEXI’s income statement to Excel — free account
NexImmune, Inc.
NEXI Healthcare Biotechnology
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow NEXI
| Older periods | Sep '23 | Dec '23 | Mar '24 | Jun '24 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(156.79%) | (180.64%) | (196.47%) | (232.97%) | |
| (121.49%) | (125.24%) | (130.41%) | (140.56%) | ||
ROIC |
0.00% | (7,175.68%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(561.05%) | (1,937.14%) | (977.31%) | 4,097.97% | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(35.22) | (29.99) | (16.83) | (12.34) | |
Free Cash Flow |
(36.91) | (31.47) | (21.04) | (17.04) | |
Capital Expenditures |
(0.19) | (0.04) | 0.52 | 0.57 | |
| Other line items | |||||
Cash ROIC |
(213.24%) | (467.53%) | (291.61%) | (542.46%) | |
Accounts Payable Turnover |
1.48 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
181.47 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | — | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(46.09) | — | — | — | |
Operating CF/Net income |
0.84 | 0.97 | 0.83 | 0.85 | |
Depreciation/Fixed assets |
0.29 | 0.76 | 0.71 | 0.62 | |
Capex/Depreciation |
(0.18) | (0.04) | 0.59 | 0.83 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(35.04) | (29.95) | (17.24) | (12.76) | |
Capex per Share |
(0.18) | (0.04) | 0.42 | 0.41 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates